Remove Blogging Remove Report Remove Screening Remove Study
article thumbnail

Brad Feld Drops Knowledge. Here’s What He Said …

Both Sides of the Table

Brad on blogging. How did you start blogging? “My My initial desire to blog came from something that’s always been my approach to investing – I’m a nerd and I love to play with the technology and part of my approach has really been to understand things both at a user level and at a reasonably deep tentacle level.

article thumbnail

Biotech Roundup: ASCO, BIO, Drug Setbacks, Incubators & More

Xconomy

The results give the company confidence it can expand its tests to screen for early cancer in high-risk people who are otherwise healthy. Ed Silverman at STAT reported the analyst note first. Theranos CEO Elizabeth Holmes, just like her fellow black turtleneck wearer Steve Jobs, will get the big screen treatment.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bio Roundup: Cancer Wishes and Shopping Lists, Allergan Pricing & More

Xconomy

The full report is here ; a summary is here.). Xconomy reached Tyler Jacks, the co-chair of the panel and director of the Koch Institute for Integrative Cancer Research at MIT, to ask about the report. The agency advised women and their doctors not to use screening tests that claim to detect ovarian cancer.

Pricing 40
article thumbnail

Why Online / Offline Mobile Integration is Going to be a Huge Business

Both Sides of the Table

We now know that the medium has changed the news industry leading to blogs, real-time reporting, integration of text and video, two-way discussions, stories surfaced based on what your friends are reading, etc. Early TV programs featured people sitting in chairs and reading scripts as though they were on the radio. They’re not.

Mobile 329
article thumbnail

Bio Roundup: Hope for Lungs, Bradner’s Complaint, FDA Nods & More

Xconomy

Who will be able to afford all these options? We explored that question in our coverage. The price of drugs is certainly on a lot of minds these days, including the mind of President Trump, as he reportedly will make a. Read more » Reprints | Share:

Pricing 52
article thumbnail

Biotech Roundup: Kadmon Debt, Hemo Data, Loose Lips & More

Xconomy

The filing held some surprises , however, as Xconomy reported: plans to convert about $200 million in debt—a massive amount for a privately held biotech—into shares at the IPO, with some of those shares holding special privileges for their owners. . —Ben Fidler contributed to this report. Reprints | Share:

News 55